Study details
Enrolling now
ARQ-154 Foam 0.3% Trial
Arcutis Biotherapeutics, Inc.
NCT IDNCT07340216ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
16
Study length
about 1.2 years
Ages
2–12
Locations
5 sites in AR, FL, ID +2
What this study is about
This trial is testing the safety and how well ARQ-154 foam 0.3% works in children with scalp and body psoriasis. The goal is to understand how much of the drug gets into the bloodstream (pharmacokinetics) and see if it's safe for them.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ARQ-154 Foam 0.3%
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
topical
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
topical
Endpoints
Primary: Participant incidence of adverse events
Body systems
Dermatology